TroVax®

BIOLOGICAL2 trials

Sponsors

University College, London, Wales Cancer Trials Unit

Conditions

Fallopian Tube CancerMalignantMesotheliomaOvarian CancerPeritoneal CancerPleural

Phase 2

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer

CompletedNCT01556841

University College, LondonFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Start: 2013-11-30End: 2019-04-19Updated: 2019-05-09

A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma

Wales Cancer Trials UnitMalignant, Mesothelioma, Pleural

Start: 2012-12-31End: 2014-12-31Target: 26Updated: 2013-03-12

Related Papers

A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).

2024-08-052 citations

TRIOC: A randomised parallel group double-blind phase II study to assess the activity of MVA-5T4 vaccine versus placebo in patients with relapsed asymptomatic epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology2016-05-201 citations